Browsing Tag
Pacibekitug
1 post
Why is Novartis acquiring Tourmaline Bio—and how does pacibekitug fit into its cardiovascular pipeline?
Novartis is acquiring Tourmaline Bio in a $1.4B deal to advance pacibekitug, a promising anti-IL-6 therapy for atherosclerotic cardiovascular disease.